Drug Type Monoclonal antibody |
Synonyms S-531011 |
Target |
Action modulators |
Mechanism CCR8 modulators(CCR8 chemokine modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Esophageal Squamous Cell Carcinoma | Phase 2 | United States | 30 May 2022 | |
Esophageal Squamous Cell Carcinoma | Phase 2 | Japan | 30 May 2022 | |
Gastroesophageal junction adenocarcinoma | Phase 2 | United States | 30 May 2022 | |
Gastroesophageal junction adenocarcinoma | Phase 2 | Japan | 30 May 2022 | |
Melanoma | Phase 2 | United States | 30 May 2022 | |
Melanoma | Phase 2 | Japan | 30 May 2022 | |
Metastatic Solid Tumor | Phase 2 | United States | 30 May 2022 | |
Metastatic Solid Tumor | Phase 2 | Japan | 30 May 2022 | |
Non-Small Cell Lung Cancer | Phase 2 | United States | 30 May 2022 | |
Non-Small Cell Lung Cancer | Phase 2 | Japan | 30 May 2022 |